Home
Products and Services
Product Center
Customer Service
R&D and Quality
Quality System
R & D Center
Blog
Company News
Industry Information
Media Coverage
About
Introduction
Culture
Corporate Honors
Recruitment
Contact
Industry News
What are pharmaceutical intermediates, APIs
The so-called pharmaceutical intermediates are actually some chemical raw materials or chemical products used in the process of drug synthesis.
12
2021
/
China Cephalosporin Drugs and Intermediates Market Analysis
Under the influence of the epidemic and the price reduction of the collection, the domestic cephalosporin drug market has a more obvious decline in the past three years, and in 2022 it was 57.555 billion yuan.
Antibiotic intermediates: varieties of differentiation is obvious, industrial upgrading continues
Penicillins: prices are higher, 6-APA competition pattern eases. Penicillin intermediates mainly include penicillin industrial salt and 6-APA, penicillin industrial salt is widely used, 6-APA is an important intermediate for the production of semi-synthetic penicillin amoxicillin and ampicillin (sodium).
Linuo Pharmaceuticals to get through the ‘last kilometre’ from ‘good material’ to ‘good medicine’.
Taking advantage of the momentum to grasp the project, go all out to spell the economy.
09
2023
05
The year of the ‘three batch’: the project accelerated the development of increased momentum 丨to go all out to fight the economy-storage of new momentum
In the year 2023 just past, the project construction charge continued to blow throughout the year. What is the pulling effect of so many commissioned projects on the economic development of various places?
02
2024
01
Pharmaceutical intermediates have become an important link in the pharmaceutical industry chain
Pharmaceutical intermediates are important raw materials in the process of manufacturing drugs, and the quality of pharmaceutical intermediates directly determines the quality and effect of drugs.
16
2025
2024 medical insurance state talks: 91 kinds of drugs new enhancement catalogue, negotiation average price reduction of 63%
At the conference, the relevant person in charge of the National Health Insurance Bureau introduced that the scope of catalogue adjustment this year is mainly based on new medicines, and 90 of the 91 new medicines are newly listed varieties within five years.
2023 China Pharmaceutical Enterprises R&D Achievement Index Released, Gaining Insight into the Industry's Innovation Pulse
Recently, the ‘2023 R&D Index of Chinese Pharmaceutical Enterprises’ was officially released at the 2024 China Pharmaceutical Industry Development Conference.